Navigation Links
InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
Date:1/5/2012

BRISBANE, Calif., Jan. 5, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced unaudited net sales of Esbriet® (pirfenidone) for the fourth quarter ended December 31, 2011, as well as information on the number of patients that initiated Esbriet therapy in Germany during 2011.  InterMune also highlighted its recent business and clinical development activities, including new efficacy data from the RECAP extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), and provided forward-looking operating expense guidance for 2012. 

Esbriet Launch in Germany 

InterMune estimates that approximately 612 patients have been prescribed Esbriet in Germany since the mid-September launch.  Of these 612 patients, approximately 172 patients were enrolled in the Named Patient Program (NPP) in Germany and were transitioned to commercial supply during the recently completed quarter.  The balance, or approximately 440 patients were prescribed Esbriet as new patients during the quarter. 

A total of 410 patients were enrolled in the NPP outside of Germany as of December 31, 2011, bringing the total number of new patient starts on Esbriet therapy across Europe to approximately 1,022 during 2011.

InterMune today reported that unaudited net sales of Esbriet in Germany during the fourth quarter of 2011 totaled approximately $2.7 million.  Unaudited net sales of Esbriet totaled approximately $2.8 million since its launch in mid-September 2011.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "We are extremely pleased that the German launch of Esbriet, the first commercial launch in Europe, continues to meet our high expectations both qualitatively and quantitatively.  These early results affirm our view that Esbriet has the potenti
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. InterMune Appoints Angus C. Russell to Board of Directors
2. InterMune to Release Third Quarter Financial Results on November 3
3. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
4. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
5. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
6. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
7. InterMune to Present at J.P. Morgan Healthcare Conference
8. InterMune Reports Third Quarter 2010 Financial Results
9. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
10. InterMune to Release Second Quarter Financial Results on July 27
11. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Colo. , July 23 2014 Ampio ... of its new headquarters, manufacturing and research facility: ... CO 80112 Direct: (720) 437-6500 ... labor efficient, pharmaceutical drug manufacturing facility will be fully ... produce the first batches of Ampion TM necessary ...
(Date:7/23/2014)... 2014 Pelvalon, Inc. is making its clinical ... Washington, D.C. with the presentation of ... Vaginal Bowel Control (VBC) System.  Holly E. Richter ... and Pelvic Reconstructive Surgery at the University of Alabama ... for Gynecological Surgeons (SGS), served as the National Principal ...
(Date:7/23/2014)... July 23, 2014 Research and ... "Emulsifiers - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769 This report analyzes ... and US$ Thousands by the following Product Segments: ... Polysorbates and Sorbitan Esters, and Polyglycin Polyricinoleate & ...
Breaking Medicine Technology:Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2Pelvalon Announces Results from the LIFE Pivotal Trial at the 2014 AUGS/IUGA Conference 2Emulsifiers - Global Strategic Business Report: Updated 2014 Report 2Emulsifiers - Global Strategic Business Report: Updated 2014 Report 3
... (Nasdaq: LMNX ) today announced that it expects ... Monday, April 30, 2012. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the first quarter ended March 31, ...
... FARMINGTON, Conn., April 9, 2012 /PRNewswire-iReach/ -- Global ... 3 significant Drug Discovery and Healthcare conferences scheduled for Boston, ... CHI and Bio-IT World,s 12th Annual Structure-Based Drug Design Conference ... Structure-based drug design took nearly two decades to arrive at ...
Cached Medicine Technology:Luminex Corporation First Quarter Earnings Release Scheduled for April 30, 2012 2Luminex Corporation First Quarter Earnings Release Scheduled for April 30, 2012 3Boston to Host 3 Major Annual Drug Discovery Conferences, Early Bird Expiring April 27 2Boston to Host 3 Major Annual Drug Discovery Conferences, Early Bird Expiring April 27 3
(Date:7/23/2014)... Low enrollment and higher-than-expected administrative ... come up with alternative means to becoming self-sustaining. ... to accomplish this in the July 17 issue ... (HEX). , “We never expected the operating budgets ... Condeluci, an attorney at the law firm Venable ...
(Date:7/23/2014)... DBC Pri-Med LLC , the leading ... more than 260,000 clinicians and the University of South ... national continuing medical education (CME) curriculum to educate and ... ultrasound and how to utilize these technologies at the ... Carolina School of Medicine will deliver its first education ...
(Date:7/23/2014)... TeraGanix has recently announced the ... located only 4.5 miles off of highway I-8. The new ... accessibility for businesses in the Arizona region that use its ... Its Casa Grande location is only 1 hour away from ... from Phoenix. With over 26 million acres of agricultural ...
(Date:7/23/2014)... VA (PRWEB) July 23, 2014 According ... residential real estate transactions throughout the region, the ... trends in June. Homes are selling quickly throughout the ... parts of the region. The Northern Virginia market includes ... Prince William counties. , The Northern Virginia region saw ...
(Date:7/23/2014)... Townsend Security, a leading authority in data ... security solutions now support two factor authentication. This major ... relying on passwords as their only authentication mechanism. , ... Two Factor Authentication software with the following Alliance ... Alliance AES/400 – High performance, NIST validated AES encryption ...
Breaking Medicine News(10 mins):Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 2Health News:Industry Observers Tell AIS They Predict Changes to Exchange User Fees, Platforms 3Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 2Health News:Pri-Med and the University of South Carolina School of Medicine Launch National Ultrasound Education Initiative for Primary Care Clinicians 3Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 2Health News:TeraGanix Opens New Arizona-Based Agricultural Products Supply Facility 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Announces Median Sale Price Increased in the Region in June 2014 2Health News:Townsend Security Brings Two Factor Authentication to Leading IBM i Security Solutions 2
... April 24 Foundation for,Biomedical Research (FBR) Board Chairman ... the highest civilian honor Congress can,bestow, on Wednesday., ... the world of science,are few, but they are iconic ... said President George W. Bush. "Today we gather to ...
... and Employment,Discrimination, BAYSIDE, N.Y., April 24 ... hailed today,s vote in the,United States Senate ... (GINA), to ban genetic discrimination in,health insurance ... GINA,in April 2007., "TSA has worked ...
... First Patient Receives Cimzia(R) Dose through CIMplicity(TM) within Two ... ... April 24 UCB announced today the launch of its,CIMplicity(TM) ... to severe Crohn,s disease. CIMplicity(TM) provides,Cimzia(R) patients and their caregivers ...
... at Long Beach Veterans Administration Hospital, LONG ... Administration will honor Dr. Richard Merkin, President of,Heritage ... of American,war veterans. The VA, in collaboration with ... research study aimed at,examining diabetic ulcers in veterans. ...
... at 11:00,am, Family Research Council will present a lecture ... Health Policy Studies. Mr.,Moffit will discuss why health care ... applications in medicine, e.g. the,right to choose a pro-life ... the life of a loved one. To have these ...
... of Seniors Act, WASHINGTON, April 24 The ... to preventing,unintentional home injuries, applauds today,s enactment of the ... President Bush yesterday, comes,at a critical time when each ... and about 30 percent of those who fall require ...
Cached Medicine News:Health News:Michael E. DeBakey Receives Congressional Gold Medal 2Health News:Tourette Syndrome Association Applauds the Passage of Genetic Information Nondiscrimination Act 2Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 2Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 3Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 4Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 5Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 6Health News:UCB Launches CIMplicity(TM) Program to Enhance Treatment Support for Cimzia(R) (certolizumab pegol) Patients and Caregivers 7Health News:Veterans Honor Dr. Richard Merkin During Research Week 2Health News:President Signs Elder Falls Bill Into Law 2
... The Veris physiological monitor offers a comprehensive ... specifically designed for pediatric and neonate patients, ... to 3T. Veris is the first MR ... of pediatric and neonate patient monitoring. The ...
The SonoSite MicroMaxx gives you big machine performance in a lightweight package. This laptop-sized, durable unit represents the technology crossover point between hand-carried ultrasound and larger...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
... is a fully automated ... for clotting, photometric and ... tests.The medium-throughput analyser offers ... tubes, 45 reagents onboard, ...
Medicine Products: